- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04434248
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At the pilot stage: upon signing the informed consent form and screening, 60 eligible patients with polymerase chain reaction (PCR) confirmed COVID-19 pneumonia are randomized at a 1:1:1 ratio to receive either Favipiravir 1600 mg twice a day (BID) on Day 1 followed by 600 mg BID on Days 2-14 (1600/600 mg), or Favipiravir 1800 mg BID on Day 1 followed by 800 mg BID on Days 2-14 (1800/800 mg), or SOC.
At the pivotal stage: additional 270 eligible patients are randomized at a 1:1 ratio to receive either Favipiravir (the dose regimen depends of the subject's weight) or SOC.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Makhachkala, Russian Federation
- Republican Clinical Hospital
-
Moscow, Russian Federation
- First Moscow State Medical University n.a. I.M. Sechenov
-
Moscow, Russian Federation
- "K+31" Clinic
-
Moscow, Russian Federation
- "Khaven" Llc
-
Moscow, Russian Federation
- Central Clinical Hospital with Polyclinic
-
Moscow, Russian Federation
- Central Research Institute of Epidemiology
-
Moscow, Russian Federation
- City Clinical Hospital n.a. O.M. Filatov
-
Moscow, Russian Federation
- City clinical hospital named after S.S. Yudin
-
Moscow, Russian Federation
- City Clinical Hospital No. 24
-
Moscow, Russian Federation
- City Clinical Hospital No. 51
-
Moscow, Russian Federation
- Moscow State University n.a. M. V. Lomonosov
-
Moscow, Russian Federation
- National Medical and Surgical Center named after N.I. Pirogov
-
Nizhny Novgorod, Russian Federation
- City Hospital № 33 of the Leninsky region of Nizhny Novgorod
-
Nizhny Novgorod, Russian Federation
- Infectious clinical hospital No.2 of Nizhny Novgorod
-
Ryazan, Russian Federation
- Ryazan State Medical University named after I.P. Pavlov
-
Saint Petersburg, Russian Federation
- Military Medical Academy named after S.M. Kirova
-
Saratov, Russian Federation
- Saratov State Medical University named after V.I. Razumovsky
-
Smolensk, Russian Federation
- Clinical hospital No.1
-
Tver, Russian Federation
- Regional Clinic Hospital
-
Ufa, Russian Federation
- Bashkir State Medical University
-
Yakutsk, Russian Federation
- Yakutsk City Clinical Hospital
-
Yaroslavl, Russian Federation
- Yaroslavl Regional Clinical Hospital for War Veterans
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Patient Information Sheet and Informed Consent form to participate in the study.
- Men and women aged 18 years and older.
- Patients hospitalized with a diagnosis of COVID-19.
- The diagnosis of COVID-19 was confirmed by positive reverse transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2, performed no earlier than 7 days before hospitalization or at screening.
Moderate severity of COVID-19 with pneumonia with at least 1 of the following symptoms:
- Fever above 38 °C;
- Cough;
- Shortness of breath during physical exertion;
- C reactive protein (CRP) of blood serum > 10 mg/l;
- SpO2 < 95%
- The capability of oral drug administration.
- The patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion.
Exclusion Criteria:
Severe type of disease, with at least one of the following criteria:
- Frequency of breath > 35 per minute, which does not decrease after the body temperature drops to normal or subfebrile values;
- Blood oxygen saturation (SpO2) < 90% at rest;
- Partial pressure of oxygen in arterial blood (PaO2) < 60 mm Hg;
- Oxygenation index (RaO2/FiO2) ≤ 200 mm Hg;
- Partial pressure of CO2 in arterial blood (PaCO2) < 60 mm Hg;
- Septic shock.
- Patients treated with lopinavir/ritonavir, ribavirin, arbidol, chloroquine, hydroxychloroquine, mefloquine, favipiravir within 7 days prior to screening.
- Severe cardiovascular diseases currently or 6 months prior to randomization, including: New York Heart Association (NYHA) Class III or IV chronic heart failure, clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction, heart and coronary vessel surgery, significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure > 180 mm Hg and diastolic blood pressure > 110 mm Hg, pulmonary embolism or deep vein thrombosis.
- Severe chronic renal impairment (GFR < 30 ml / min) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis.
- A history of cirrhosis or an increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) > 5 times × upper limit of normal (ULN).
- Severe diseases of the central nervous system, including seizures in history or conditions that may lead to their development; stroke or transient ischemic attack within 12 months prior to screening; head injuries or loss of consciousness within 12 months prior to screening; a brain tumor.
- Significant uncontrolled concomitant disease, e.g. neurological, renal, hepatic, endocrinological or gastrointestinal disorder which according to the Investigator, could prevent the patient from participating in the study
- Malignancies that require chemotherapy within 6 months prior to screening.
- Known HIV infection
- Hypersensitivity to any component of the study drug.
- Participation in other clinical studies or taking other study drugs within 28 days prior to screening.
- Pregnant or lactating women or women planning to get pregnant during the clinical study; women of child-bearing potential (including non-sterilized by surgical means and during the post-menopause period less than 2 years) who do not use adequate contraception methods.
- Inability to read or write, unwillingness to understand and follow procedures of study protocol, as well as any other concomitant medical or serious mental conditions that make the patient unfit to participate in the study, limit the legality of obtaining informed consent or can affect patient's ability to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Favipiravir, lower dose (pilot stage)
1600mg BID on the 1st day followed by 600mg BID for 13 days
|
200 mg coated tablets
Other Names:
|
Experimental: Favipiravir, higher dose (pilot stage)
1800mg BID on the 1st day followed by 800mg BID for 13 days
|
200 mg coated tablets
Other Names:
|
Active Comparator: Standard of care (pilot stage)
Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir).
Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
|
Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
Other Names:
|
Experimental: Favipiravir, selected dose (pivotal stage)
The dose will be selected based on pilot study results.
|
200 mg coated tablets
Other Names:
|
Active Comparator: Standard of care (pivotal stage)
Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir).
Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
|
Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of viral elimination by Day 10 [pilot stage, dose selection]
Time Frame: 10 Days
|
Percent of patients with undetectable SARS-CoV-2 RNA level on Day 10
|
10 Days
|
Time to viral elimination [pivotal stage]
Time Frame: 28 Days
|
Median time to reach undetectable SARS-CoV-2 RNA level
|
28 Days
|
Time to clinical improvement [pivotal stage]
Time Frame: 28 Days
|
Median time reach clinical improvement (2 points of the Ordinal Scale for Clinical Improvement) or discharge from the hospital
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of viral elimination
Time Frame: Days 3, 5, 7, 9, and 11
|
Percent of patients with undetectable SARS-CoV-2 RNA level
|
Days 3, 5, 7, 9, and 11
|
Time to normalization of clinical symptoms
Time Frame: 28 Days
|
Median time [days] to reach normal levels of clinical indicators (body temperature, SpO2, breathing rate)
|
28 Days
|
Duration of oxygen therapy
Time Frame: 28 Days
|
Mean duration of oxygen therapy [days]
|
28 Days
|
Change in the level of lung damage according to CT
Time Frame: Days 15, 22, and 29
|
Change of lung damage level according to CT comparing to baseline [% of patients]
|
Days 15, 22, and 29
|
Rate of transfer to the intensive care unit
Time Frame: 28 days
|
Percent of patients transferred to the intensive care unit [% of patients]
|
28 days
|
Rate of the use of non-invasive lung ventilation
Time Frame: 28 days
|
Percent of patients undergoing non-invasive lung ventilation [% of patients]
|
28 days
|
Rate of the use of mechanical ventilation
Time Frame: 28 days
|
Percent of patients undergoing mechanical ventilation [% of patients]
|
28 days
|
Mortality
Time Frame: 28 days
|
Percent of patients died within 28-days period [% of patients]
|
28 days
|
Peak plasma concentration (Cmax)
Time Frame: Day 1
|
Determination of Cmax [ng/ml]
|
Day 1
|
Time to peak plasma concentration (Tmax)
Time Frame: Day 1
|
Determination of Tmax [h]
|
Day 1
|
Area under the plasma concentration versus time curve (AUC0-t)
Time Frame: 10 days
|
Determination of AUC0-t [ng*h/ml]
|
10 days
|
Trough plasma concentration (Ctrough)
Time Frame: 10 days
|
Determination of Ctrough [ng/ml]
|
10 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elena Pavlikova, MD,PhD,Prof, Moscow State University n.a. M.V. Lomonosov
- Principal Investigator: Nikita Lomakin, MD,PhD, Central Clinical Hospital with Polyclinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antirheumatic Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Antimalarials
- Amebicides
- Favipiravir
- Ritonavir
- Lopinavir
- Chloroquine
- Hydroxychloroquine
Other Study ID Numbers
- COVID-FPR-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Favipiravir
-
Institut National de la Santé Et de la Recherche...FUJIFILM Toyama Chemical Co., Ltd.Not yet recruitingInfectious Disease | PharmacologyFrance
-
Appili Therapeutics Inc.University Health Network, Toronto; Sunnybrook Health Sciences Centre; University... and other collaboratorsTerminated
-
MDVI, LLCMediVector, Inc.CompletedInfluenzaUnited States, Russian Federation, Turkey, Spain, Belgium, Hungary, South Africa, Bulgaria, Ukraine, Poland, Netherlands, Australia, New Zealand, Sweden
-
MDVI, LLCMediVector, Inc.CompletedInfluenzaUnited States, Canada, Brazil, Mexico, Colombia, Argentina, Peru, Puerto Rico, Guatemala, Dominican Republic, El Salvador
-
Atabay Kimya Sanayi Ticaret A.S.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiCompleted
-
Peking University First HospitalUnknown
-
World Medicine ILAC SAN. ve TIC. A.S.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiCompleted
-
Beijing Chao Yang HospitalUnknownNovel Coronavirus PnuemoniaChina
-
Ministry of Health, TurkeyIstanbul University; Ankara Training and Research Hospital; Prof. Dr. Cemil Tascıoglu... and other collaboratorsActive, not recruitingCOVID-19 | Sars-CoV2Turkey
-
University of PecsHungarian Ministry of Innovation and TechnologyTerminatedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Hungary